PITTSBURGH, Aug. 23, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, presented today the results of one of its Phase 2 studies* of cenerimod (ACT-333441). The ACT-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th Asia-Pacific League of Associations for Rheumatology (APLAR) Annual Congress. The congress is being held August 21-25, 2024, in Suntec, Singapore.
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business
PITTSBURGH, Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on September 13, 2024, to shareholders of record as of the close of business on August 23, 2024.
Aug 5 (Reuters) - Novartis (NOVN.S), opens new tab and Viatris (VTRS.O), opens new tab were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Enforcement Report - Week of July 24, 2024
Viatris, a global healthcare company, announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures.
Calliditas Therapeutics AB (Calliditas) announces that its partner Viatris Pharmaceutical Japan G.K. (Viatris) has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).
PITTSBURGH, July 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures.